Sunstone Life Science Ventures leads EUR 10 million Series A financing round in Resalis Therapeutics

Italian-based Resalis Therapeutics has successfully secured EUR 10 million in a Series A financing round. The round was led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors. Mazanti Transactions advised long-term client Sunstone Life Science Ventures in connection with the investment emphasizing the team’s expertise in navigating complex transactions in the life science sector.

Resalis Therapeutics focuses on combating metabolic disorders through innovative non-coding RNA (ncRNA)-based therapeutics, potentially enhancing the effectiveness of existing treatments. The company's lead candidate, RES-010, is designed to provide a disease-modifying approach in obesity with longer-lasting weight reduction and the ability to extend treatment durability in combination with approved therapeutics, such as GLP-1 receptor agonists.

While GLP-1 receptor agonists continue to post impressive weight loss data, the drugs face several shortcomings in obesity, including the duration of effect after treatment ends. Resalis is aiming to fill those holes with a complementary therapy ensuring longer-lasting weight reduction.

The funding will support Resalis in initiating and completing the first-in-human Phase 1 clinical trial for RES-010 evaluating the safety and efficacy of it and reach Phase 2 readiness.

In conjunction with the financing, Claus Andersson, General Partner of Sunstone Life Science Ventures, will join Resalis' Board of Directors.

Mazanti Transactions advised Sunstone Life Science Ventures in connection with the entire investment process.